In this scenario, recent studies have highlighted that the deletion and/or mutation of ARID1A increases the efficiency of EBV infection in gastric epithelial cells, linking genetic alterations in GC with viral infection, and suggesting potential novel avenues of therapeutic intervention [59,60]. Here, ARID1A is linked to gastric cancer.